key: cord-0806675-asd0jkm7
authors: Tee, M. W.; Avarbock, A. B.; Ungar, J.; Frew, J. W.
title: Rapid Resolution of Pyoderma Gangrenosum with Brodalumab Therapy
date: 2020-09-14
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2020.08.033
sha: 1e55bb9f1096221692de14b1bdcaff0c0c80f7d6
doc_id: 806675
cord_uid: asd0jkm7

nan

Pyoderma Gangrenosum (PG) is a burdensome ulcerative dermatosis, which presents in isolation or in association with other inflammatory conditions (e.g. inflammatory bowel disease) 1 . PG can be therapeutically challenging, especially when first line treatments (such as oral corticosteroids and cyclosporine) fail to resolve the condition 1,2 . Whilst IL-17 and IL-23 antagonism has been suggested to ameliorate disease activity, only case reports using Secukinumab therapy currently exist 2 . We report two cases of PG which demonstrated rapid resolution in response to Brodalumab 210mg/1.5mg for co-existing Hidradenitis Suppurativa The slower improvement in patient 2 concurs with findings in HS that weekly Brodalumab dosing provides more rapid disease control than EOW dosing 3 . This may be due to receptormediated clearance by neutrophils (Brodalumab binding to neutrophils and removal in the form of pus) in a mechanism similar to that proposed in HS 4 . Alternatively, Brodalumab therapy may be more effective in small lesions or more superficial variants of PG (patient 1) rather than larger ulcerative lesions (patient 2).

Although larger placebo-controlled studies as well as studies in idiopathic PG (without coexistent HS) are needed, these case reports suggest that Brodalumab 210mg weekly results in rapid resolution of PG. EOW dosing may also aid resolution of PG, however resolution is likely to be significantly slower than with weekly dosing. 

Ortega-Loayza AG Biologic and Small-Molecule Medications in the Management of Pyoderma Gangrenosum

Weekly Administration of Brodalumab in Hidradenitis Suppurativa: An Open Label Cohort Study

The Effect of Subcutaneous Brodalumab upon Clinical Disease Activity in Hidradenitis Suppurativa: An Open Label Cohort Study